If you like the Plenary Session podcast, you will love The Drug Development Letter. Here, we explore all aspects of pharmaceutical drug development from early phase to late phase and FDA approval. While the focus will likely be cancer drugs, we will also cover important cardiology, neurology, and drugs for rare diseases.

Who am I?

I’m Vinay Prasad MD MPH, a Professor of Epidemiology, Biostatistics and Medicine at the University of California, San Francisco. I am the author of 450 peer reviewed papers, and two books: Ending Medical Reversal and Malignant. I host the popular podcasts Plenary Session and co-host the VPZD show. I run the vkprasadlab, which studies drug development.

Why subscribe?

Subscribe to get full access to the newsletter and website. Never miss an update.

Free subscribers will get access to all posts about late phase drug development (Phase 2/3 and pivotal registration studies)

Paying subscribers will get access to all that, as well as detailed explorations of early phase products, with special emphasis on products made by companies that have no other products on the US market. This will probably only interest serious drug development people.

Stay up-to-date

You won’t have to worry about missing anything. Every new edition of the newsletter goes directly to your inbox.

Join the crew

Be part of a community of people who share your interests.

To find out more about the company that provides the tech for this newsletter, visit Substack.com.

Subscribe to The Drug Development Letter

We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases


Hematology Oncology Medicine Health Policy Epidemiology Professor